Tempus AI (NASDAQ:TEM) CAO Ryan Bartolucci Sells 7,062 Shares of Stock

Posted by Brenda Bartman on Sep 19th, 2026

Tempus AI, Inc. (NASDAQ:TEM – Get Free Report) CAO Ryan Bartolucci sold 7,062 shares of the business’s stock in a transaction dated Thursday, September 17th. The shares were sold at an average price of $75.00, for a total transaction of $529,650.00. Following the completion of the transaction, the chief accounting officer owned 60,804 shares in the company, valued at $4,560,300. The trade was a 10.41% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Tempus AI Stock Performance

Tempus AI stock opened at $77.84 on Friday. The company has a current ratio of 3.30, a quick ratio of 3.16 and a debt-to-equity ratio of 3.06. The firm has a market cap of $14.04 billion, a P/E ratio of -54.06 and a beta of 3.72. Tempus AI, Inc. has a 1-year low of $40.77 and a 1-year high of $104.32. The firm has a 50-day moving average of $57.19 and a 200-day moving average of $52.90.

Tempus AI (NASDAQ:TEM – Get Free Report) last announced its quarterly earnings results on Thursday, July 30th. The company reported ($0.04) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.10. The company had revenue of $382.49 million for the quarter, compared to the consensus estimate of $379.69 million. Tempus AI had a negative return on equity of 50.28% and a negative net margin of 17.77%.Tempus AI’s revenue was up 21.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.22) EPS. Sell-side analysts expect that Tempus AI, Inc. will post -1.38 EPS for the current year.

Hedge Funds Weigh In On Tempus AI

Institutional investors have recently added to or reduced their stakes in the company. Amova Asset Management Americas Inc. raised its stake in Tempus AI by 23.4% during the first quarter. Amova Asset Management Americas Inc. now owns 4,326,313 shares of the company’s stock valued at $195,549,000 after buying an additional 821,490 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. grew its stake in shares of Tempus AI by 23.4% in the first quarter. Sumitomo Mitsui Trust Group Inc. now owns 4,326,313 shares of the company’s stock worth $195,636,000 after acquiring an additional 821,490 shares during the last quarter. Norges Bank purchased a new stake in shares of Tempus AI in the fourth quarter worth $48,234,000. Franklin Resources Inc. grew its stake in shares of Tempus AI by 27.9% in the fourth quarter. Franklin Resources Inc. now owns 1,861,782 shares of the company’s stock worth $109,938,000 after acquiring an additional 405,662 shares during the last quarter. Finally, Lingotto Investment Management LLP increased its holdings in shares of Tempus AI by 45.9% during the fourth quarter. Lingotto Investment Management LLP now owns 1,143,526 shares of the company’s stock valued at $67,525,000 after acquiring an additional 359,667 shares in the last quarter. Institutional investors own 24.22% of the company’s stock.

Trending Headlines about Tempus AI

Here are the key news stories impacting Tempus AI this week:

Positive Sentiment: CEO commentary outlining Tempus AI’s growth strategy and projected Medicare revenue has strengthened confidence that reimbursement expansion could provide a significant new revenue stream. Tempus AI Stock Roars Back 92% From July Low After CEO Lays Out Growth Plan
Positive Sentiment: Morgan Stanley’s updated outlook reportedly incorporated additional reimbursement-driven revenue potential, helping fuel a sharp weekly advance in TEM shares and reinforcing the bullish growth narrative. Tempus AI Is Ripping 30% Higher This Week After Morgan Stanley Boosts Revenue Outlook
Positive Sentiment: Trading momentum remains strong: shares have rebounded roughly 92% to 95% from the July low, with market capitalization moving above $14 billion. Above-average volume and elevated call-option activity indicate substantial speculative interest. Tempus AI Stock Is Soaring
Neutral Sentiment: Analysts and market commentators are assessing whether the recent surge can continue. The rally has improved sentiment, but the sharp move also raises the risk of profit-taking and increased volatility. Strength Seen in Tempus
Negative Sentiment: Zacks cautioned that recent earnings-estimate revision trends may not support another near-term advance, while brokerages maintain an average “Hold” rating. Tempus also remains unprofitable, making the stock particularly sensitive to valuation concerns and changes in growth expectations. Tempus AI Receives Average Hold Rating

Wall Street Analyst Weigh In

Several research analysts have commented on TEM shares. Guggenheim upped their price objective on shares of Tempus AI from $60.00 to $65.00 and gave the stock a “buy” rating in a report on Thursday, July 16th. Needham & Company LLC reiterated a “buy” rating and set a $75.00 price target on shares of Tempus AI in a research report on Friday, July 31st. TD Cowen reiterated a “buy” rating on shares of Tempus AI in a research report on Wednesday, July 15th. Cantor Fitzgerald initiated coverage on shares of Tempus AI in a research note on Wednesday, September 2nd. They issued an “overweight” rating and a $80.00 price target for the company. Finally, Piper Sandler upgraded shares of Tempus AI from a “neutral” rating to an “overweight” rating and raised their price objective for the stock from $56.00 to $76.00 in a report on Tuesday, September 1st. Eleven research analysts have rated the stock with a Buy rating, eight have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $69.33.

View Our Latest Research Report on Tempus AI

Tempus AI Company Profile

(Get Free Report)

Tempus AI, Inc is a healthcare technology company focused on applying artificial intelligence and data analytics to precision medicine. The company combines molecular testing, clinical data and machine learning to help physicians make more informed treatment decisions and support the development of new therapies.

Tempus provides genomic and diagnostic testing services, including testing intended to identify clinically relevant mutations and other biomarkers. Its technology platform also organizes and analyzes clinical and molecular data, while its AI-enabled tools are designed to assist healthcare professionals with patient care, research and workflow management.

The company serves healthcare providers, patients, pharmaceutical companies and biotechnology researchers, primarily in the United States.